Table 2.
Parameter estimates of the final base model, placebo model, and drug effect model as provided in the Supplementary simulation model code
| THETA in NM simulation code | Parameter description (unit) | Estimated value | Estimate of variance of IIV on parameter (THETA number) |
|---|---|---|---|
| Baseline model | |||
| 9 | Correlation between disease severity at baseline on positive and negative scale (–) | −0.108 | — |
| 10 | Correlation between disease severity at baseline on positive and general scale (–) | 0.525 | — |
| 19 | Correlation between disease severity at baseline on negative and general scale (–) | 0.384 | — |
| Placebo model | |||
| 65 | Weibull asymptote positive scale (–) | −0.413 | 4.22 (TH(1)) |
| 68 | Weibull asymptote negative scale (–) | −0.173 | 2.21 (TH(2)) |
| 71 | Weibull asymptote general scale (–) | −0.144 | 5.78 (TH(1)*TH(64)) |
| 66 | Half‐life positive scale (days) | 8.47 | 0.328 (TH(3)) |
| 69 | Half‐life negative scale (days) | 11.3 | 0.498 (TH(4)) |
| 72 | Half‐life general scale (days) | 10.2 | 0.325 (TH(5)) |
| 67 | Weibull exponent positive scale (–) | 2.86 | — |
| 70 | Weibull exponent negative scale (–) | 2.46 | — |
| 73 | Weibull exponent positive scale (–) | 1.96 | — |
| 21 | Correlation disease severity at baseline and Weibull asymptote negative scale (–) | −0.182 | — |
| 13 | Correlation disease severity at baseline and half‐life positive scale (–) | 0.106 | — |
| ‐ | Correlation Weibull asymptote on positive and general scale (–) | 1 FIX | — |
| 36 | Correlation Weibull asymptote on positive/general scale and negative scale (–) | 0.895 | — |
| 49 | Correlation half‐life on positive and negative scale (–) | 0.563 | — |
| 50 | Correlation half‐life on positive and general scale (–) | 0.882 | — |
| 54 | Correlation half‐life on negative and general scale (–) | 0.673 | — |
| Drug effect model | |||
| 74 | Drug effect positive scale (–) | −1.30 | 0.193 (TH(6)) |
| 75 | Drug effect negative scale (–) | −0.572 | 0.0214 (TH(7)) |
| 76 | Drug effect general scale (–) | −1.03 | 0.00719 (TH(8)) |
| Derived from 77 | Half‐life to reach full drug effect positive scale (days) | 8.21 | — |
| Derived from 78 | Half‐life to reach full drug effect negative scale (days) | 13.1 | — |
| Derived from 79 | Half‐life to reach full drug effect general scale (days) | 5.98 | — |
| 16 | Correlation disease severity at baseline and drug effect positive scale (–) | −0.468 | — |
| 26 | Correlation disease severity at baseline and drug effect negative scale (–) | −0.495 | — |
| 62 | Correlation drug effect on positive and general scale (–) | −0.721 | — |
| Dropout model | |||
| 80 | Intercept | −5.29 | — |
| 81 | Time slope parameter (day−1) | −0.0027 | — |
| 82 | Time peak (day) | 29.6 | — |
| 83 | Parameter related to previous observed PANSS score | 0.0175 | — |
| 84 | Parameter related to difference between the last two observed PANSS scores | 0.0454 | — |
| 85 | Parameter related to difference between the previous observed PANSS score and baseline score | 0.0285 | — |
| 86 | Parameter included for patients of studies in US | 0.768 | — |
| 87 | Parameter included in first after two weeks, when patients were discharged during the study | −0.374 | — |
| 88 | Parameter included for patients receiving 15 mg paliperidon | −0.397 | — |